GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
04 Jun 2025 07:00 AM
RNS
GSK - second tranche of share buyback programme
04 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
03 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
02 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
02 Jun 2025 03:00 PM
RNS
Total Voting Rights
02 Jun 2025 07:00 AM
RNS
Linerixibat file accepted for review by US FDA
02 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
30 May 2025 07:00 AM
RNS
Transaction in Own Shares
29 May 2025 07:00 AM
RNS
Transaction in Own Shares
28 May 2025 12:00 PM
RNS
GSK stops Phase 3 trial on cUTIs for efficacy
28 May 2025 07:00 AM
RNS
Transaction in Own Shares
27 May 2025 07:00 AM
RNS
Transaction in Own Shares
23 May 2025 12:16 PM
RNS
positive CHMP opinion on Blenrep in EU
23 May 2025 07:00 AM
RNS
Transaction in Own Shares
23 May 2025 07:00 AM
RNS
FDA approves Nucala COPD indication
22 May 2025 07:00 AM
RNS
Transaction in Own Shares
21 May 2025 07:00 AM
RNS
Transaction in Own Shares
20 May 2025 03:30 PM
RNS
Director/PDMR Shareholding
20 May 2025 07:00 AM
RNS
Transaction in Own Shares
19 May 2025 07:00 AM
RNS
Blenrep for 2L+ multiple myeloma approved in Japan
19 May 2025 07:00 AM
RNS
Transaction in Own Shares
16 May 2025 07:00 AM
RNS
Transaction in Own Shares
15 May 2025 07:00 AM
RNS
Transaction in Own Shares
14 May 2025 07:00 AM
RNS
GSK to acquire efimosfermin
14 May 2025 07:00 AM
RNS
Transaction in Own Shares
13 May 2025 03:30 PM
RNS
Director/PDMR Shareholding
13 May 2025 12:56 PM
RNS
Update on belrestotug development programme
13 May 2025 07:00 AM
RNS
Transaction in Own Shares
12 May 2025 03:31 PM
RNS
Block listing Interim Review
12 May 2025 07:00 AM
RNS
Transaction in Own Shares
09 May 2025 07:00 AM
RNS
Transaction in Own Shares
08 May 2025 05:15 PM
RNS
Director/PDMR Shareholding
08 May 2025 03:30 PM
RNS
Director/PDMR Shareholding
08 May 2025 11:15 AM
RNS
Linerixibat GLISTEN pIII trial data at EASL
08 May 2025 07:00 AM
RNS
Transaction in Own Shares
07 May 2025 06:22 PM
RNS
Result of AGM
07 May 2025 07:00 AM
RNS
Transaction in Own Shares
06 May 2025 07:00 AM
RNS
Transaction in Own Shares
02 May 2025 07:00 AM
RNS
Transaction in Own Shares
01 May 2025 03:30 PM
RNS
Director/PDMR Shareholding
01 May 2025 03:00 PM
RNS
Total Voting Rights
01 May 2025 07:00 AM
RNS
Nucala MATINEE data in COPD published in NEJM
01 May 2025 07:00 AM
RNS
Transaction in Own Shares
30 Apr 2025 07:05 AM
RNS
Transaction in Own Shares
30 Apr 2025 07:00 AM
RNS
1st Quarter Results
29 Apr 2025 07:00 AM
RNS
Transaction in Own Shares
28 Apr 2025 07:00 AM
RNS
Transaction in Own Shares
25 Apr 2025 07:00 AM
RNS
Transaction in Own Shares
24 Apr 2025 07:00 AM
RNS
Transaction in Own Shares

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100